Drug Profile

EphA2 targeting radiopharmaceutical - Bicycle Therapeutics/German Cancer Research Center (DKFZ)

Latest Information Update: 05 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bicycle Therapeutics
Developer Bicycle Therapeutics; German Cancer Research Center
Class Antineoplastics; Bicyclic peptide drug conjugates; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

31 Dec 2024 Preclinical trials in Cancer in Germany (Parenteral), prior to December 2024 (Bicycle Therapeutics pipeline, December 2024)
31 Dec 2024 Preclinical trials in Cancer in United Kingdom (Parenteral), prior to December 2024 (Bicycle Therapeutics pipeline, December 2024)
04 May 2023 Bicycle Therapeutics enters into an agreement with German Cancer Research Center (DKFZ) to develop Bicycle® radio conjugates (BRCs) for Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com